A Research Study Investigating the Effect of NNC0497-0040 in Healthy Participants, Participants With Overweight or Obesity, and Participants With Type 1 Diabetes With Overweight or Obesity
← catalyst calendarNCT07578584 · readout in 547 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
146estimated
Sites
1
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-07 | actual | When the study began enrolling |
| Primary completion | 2028-02-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-02-18 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Type 1 Diabetes (T1D)
- Overweight
- Obesity
- Healthy Volunteers
Interventions
- Drug: NNC0497-0040
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFNumber of adverse events
measured Day 1 up to Week 6
Number of adverse events
measured MAD1-2: Day 1 up to Week 17; MAD3: Day 1 up to Week 25
Number of adverse events
measured Day 1 up to Week 25
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed